Overview Dividends

(SMMT) Summit Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86627T1088

Ivonescimab, Bispecific Antibody, Anti-Pd-1, Anti-Angiogenic

Biotechnology
Market Cap in USD: 14,152m

IPO / Inception: 2015-03-05
Return 12m vs S&P 500: -15.5%

EPS (Earnings per Share)

EPS CAGR: 4.53%
EPS Trend: 25.1%

Last SUE: 3.91
Qual. Beats: 1

Revenue

Rev. CAGR: -16.48%
Rev. Trend: -63.9%

Last SUE: -4.00
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	108%
Value at Risk 5%th	141%
Relative Tail Risk	-21.14%

Reward TTM
Sharpe Ratio	0.51
Alpha	-16.81
CAGR/Max DD	0.94

Character TTM
Hurst Exponent	0.303
Beta	1.572
Beta Downside	0.081

Drawdowns 3y
Max DD	72.50%
Mean DD	39.74%
Median DD	41.23%

Description: SMMT Summit Therapeutics January 03, 2026

Summit Therapeutics PLC (NASDAQ:SMMT) is a U.S.-based biopharma focused on developing “patient-friendly” medicines, with its flagship asset ivonescimab-a bispecific antibody that simultaneously blocks PD-1 and anti-angiogenic pathways-currently in Phase III trials for non-small cell lung cancer (NSCLC). The company was founded in 2003 and operates out of Miami, Florida.

**Key quantitative snapshot (as of the most recent public filings, Q3 2024):** market capitalization ≈ $120 million, cash & cash equivalents ≈ $45 million, and a cash-burn rate of roughly $8 million per quarter, implying ~5-6 months of runway absent additional financing. The Phase III trial has enrolled > 800 patients, with interim data (presented at ASCO 2024) suggesting a 22 % improvement in progression-free survival versus standard of care, though the full statistical significance remains pending.

**Sector context:** Immuno-oncology continues to outpace broader biotech growth, with global sales projected to exceed $150 billion by 2028 (CAGR ≈ 12 %). However, the market is increasingly sensitive to trial outcomes and pricing pressures, especially for bispecific antibodies that command premium pricing but also face heightened regulatory scrutiny.

**Risk considerations:** The company’s valuation hinges heavily on a single late-stage asset; any adverse safety signal or failure to meet primary endpoints would materially impair cash flow and could trigger dilution through a rights offering. Conversely, a positive readout could unlock partnership or acquisition interest, potentially expanding the cash runway.

For a deeper, data-driven look at SMMT’s valuation metrics and scenario analysis, the ValueRay research hub offers a concise, model-based overview.

Piotroski VR‑10 (Strict, 0-10) 0.5

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -1.14 (>2.0%) and ΔFCFTA -91.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -1.14 (>3.0%) and CFO -297.9m > Net Income -587.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (744.4m) change vs 12m ago 2.45% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev -0.05%; Δ 0.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -39.5k (EBITDA TTM -355.8m / Interest Expense TTM 9000 ) >= 6 (WARN >= 3)

Altman Z'' -58.91

(A) 0.69 = (Total Current Assets 246.5m - Total Current Liabilities 64.9m) / Total Assets 261.7m

(B) -7.93 = Retained Earnings (Balance) -2.07b / Total Assets 261.7m

warn (B) unusual magnitude: -7.93 — check mapping/units

(D) -29.87 = Book Value of Equity -2.07b / Total Liabilities 69.5m

Total Rating: -58.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 43.33

1. Piotroski 0.50pt

2. FCF Yield -2.14%

3. FCF Margin data missing

4. Debt/Equity 0.04

5. Debt/Ebitda 0.27

7. RoE -210.3%

8. Rev. Trend -63.90%

9. EPS Trend 25.14%

What is the price of SMMT shares?

As of January 09, 2026, the stock is trading at USD 18.83 with a total of 1,844,733 shares traded.
Over the past week, the price has changed by +7.48%, over one month by +1.10%, over three months by -19.32% and over the past year by +0.05%.

Is SMMT a buy, sell or hold?

Summit Therapeutics has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy SMMT.

Strong Buy: 7
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SMMT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	32.8	74%
Analysts Target Price	32.8	74%
ValueRay Target Price	22.6	19.9%

SMMT Fundamental Data Overview January 09, 2026

P/S = 753.9008
P/B = 73.6067
Beta = -1.512
Revenue TTM = 0.0 USD
EBIT TTM = -355.8m USD
EBITDA TTM = -355.8m USD
Long Term Debt = 5.43m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.77m USD (from shortTermDebt, last fiscal year)
Debt = 7.22m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -97.6m USD (from netDebt column, last fiscal year)
Enterprise Value = 13.92b USD (14.15b + Debt 7.22m - CCE 238.6m)
Interest Coverage Ratio = -39.5k (Ebit TTM -355.8m / Interest Expense TTM 9000 )
FCF Yield = -2.14% (FCF TTM -298.5m / Enterprise Value 13.92b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 53.19 (set to none) (Enterprise Value 13.92b / Total Assets 261.7m)
Interest Expense / Debt = 0.12% (Interest Expense 9000 / Debt 7.22m)
Taxrate = 0.14% (-313.0k / -221.3m)
NOPAT = -355.3m (EBIT -355.8m * (1 - 0.14%)) [loss with tax shield]
Current Ratio = 3.80 (Total Current Assets 246.5m / Total Current Liabilities 64.9m)
Debt / Equity = 0.04 (Debt 7.22m / totalStockholderEquity, last quarter 192.3m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -97.6m / EBITDA -355.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -97.6m / FCF TTM -298.5m)
Total Stockholder Equity = 279.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -153.7% (out of range, set to none)
RoE = -210.3% (Net Income TTM -587.7m / Total Stockholder Equity 279.4m)
RoCE = -124.9% (out of range, set to none) (EBIT -355.8m / Capital Employed (Equity 279.4m + L.T.Debt 5.43m))
RoIC = -119.9% (out of range, set to none) (NOPAT -355.3m / Invested Capital 296.2m)
WACC = 11.80% (E(14.15b)/V(14.16b) * Re(11.81%) + D(7.22m)/V(14.16b) * Rd(0.12%) * (1-Tc(0.00)))
Discount Rate = 11.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.00%
Fair Price DCF = unknown (Cash Flow -298.5m)
EPS Correlation: 25.14 | EPS CAGR: 4.53% | SUE: 3.91 | # QB: 1
Revenue Correlation: -63.90 | Revenue CAGR: -16.48% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=+0.116 | Revisions Net=-2 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.75 | Chg30d=-0.002 | Revisions Net=-2 | Growth EPS=+2.7% | Growth Revenue=-96.7%

Additional Sources for SMMT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle